The global Meningococcal Meningitis treatment market garnered a market value of US$ 170.75 Million in 2022 and is expected to accumulate a market value of US$ 283 Million by registering a CAGR of 4.7% in the forecast period 2023 to 2033. Growth of the Meningococcal Meningitis treatment market can be attributed to disease prevalence, wider availability of vaccines, and increasing awareness about the disease. The market for Meningococcal Meningitis treatment registered a CAGR of 3.1% in the historical period 2018 to 2022
Meningococcal meningitis is a serious bacterial infection that causes inflammation of the protective membranes that cover the brain and spinal cord. The treatment of meningococcal meningitis typically involves antibiotics, supportive care, and vaccination.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 178.78 Million |
| Anticipated Forecast Value (2033) | US$ 283 Million |
| Projected Growth Rate (2023 to 2033) | 4.7% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Meningococcal Meningitis treatment reflected a value of 3.1% during the historical period, 2018 to 2022.
The Meningococcal Meningitis Treatment market is primarily driven by the increasing prevalence of meningococcal meningitis, rising awareness about the disease, and increasing government initiatives to prevent and control the spread of the disease through vaccination programs. The market is also influenced by factors such as the availability and cost of antibiotics, research and development activities, and healthcare infrastructure. The market is expected to continue to grow due to the ongoing need for effective treatments and preventive measures for meningococcal meningitis.
Thus, the market for Meningococcal Meningitis treatment is expected to register a CAGR of 4.7% in the forecast period 2023 to 2033.
Increasing investment in research and development spurring growth of treatment options for Meningococcal meningitis
Meningococcal meningitis is a serious bacterial infection that can cause life-threatening complications, such as sepsis and brain damage. The increasing prevalence of meningococcal meningitis is a major driver of the Meningococcal Meningitis Treatment market.
With the increasing awareness about meningococcal meningitis, there is a greater demand for effective treatments and preventive measures. This has led to an increase in research and development activities, which has resulted in the development of new drugs and vaccines.
Governments around the world have taken measures to prevent and control the spread of meningococcal meningitis through vaccination programs, public education campaigns, and improved healthcare infrastructure. These initiatives have contributed to the growth of the Meningococcal Meningitis Treatment market.
Advancements in technology, such as the development of rapid diagnostic tests and new drug delivery systems, have improved the diagnosis and treatment of meningococcal meningitis. The increasing investment in research and development by pharmaceutical companies and other stakeholders has led to the development of new drugs and vaccines for meningococcal meningitis, which has contributed to the growth of the market.
Availability of treatments shaping landscape for Meningococcal Meningitis Treatment Market
Antibiotics: Antibiotics are the first line of treatment for meningococcal meningitis. Drugs such as penicillin, ceftriaxone, or cefotaxime are typically used to kill the bacteria causing the infection and prevent further spread. The choice of antibiotic may vary depending on the age and medical history of the patient and the severity of the infection.
Supportive care: Patients with meningococcal meningitis may require supportive care to manage symptoms and prevent complications. This can include measures such as providing fluids and electrolytes, controlling fever and seizures, and monitoring for signs of organ failure.
Vaccination: Vaccination is an important preventive measure for meningococcal meningitis. There are several vaccines available that can help protect against the bacteria that cause meningococcal disease, including serogroup B, C, Y, and W-135. Vaccination is recommended for people at high risk of meningococcal meningitis, such as children and adolescents, people living in crowded settings, and travelers to areas where the disease is common.
Corticosteroids: In some cases, corticosteroids may be used to reduce inflammation and swelling of the brain and spinal cord.
Principal Consultant
Limited availability of effective vaccines along with antibiotic resistance creating obstacles for market growth
While there are several vaccines available for meningococcal meningitis, there is still a need for more effective vaccines that can provide protection against all strains of the bacteria. The cost of antibiotics and other treatments for meningococcal meningitis can be high, making it difficult for patients to access the care they need, particularly in low-income countries.
Despite efforts to increase awareness about meningococcal meningitis, many people may not be aware of the disease or the importance of vaccination and early treatment. Overuse and misuse of antibiotics can lead to the development of antibiotic-resistant strains of the bacteria that cause meningococcal meningitis, making it more difficult to treat.
The symptoms of meningococcal meningitis can be similar to those of other infections, making it challenging to diagnose. Additionally, some people may be carriers of the bacteria without showing symptoms, making it difficult to identify and prevent outbreaks.
Demand for early detection of Meningococcal Meningitis driving market growth in North America
In North America, the meningococcal meningitis treatment market is significant due to the high incidence of the disease in the region. In addition to antibiotics, supportive care is also essential for individuals with meningococcal meningitis. This may include hospitalization, intravenous fluids to maintain hydration, and oxygen therapy to support breathing.
The increasing awareness about the disease and its potential complications is also driving market growth. The high mortality and morbidity associated with meningococcal meningitis make it a serious public health concern, and as such, there is a growing awareness about the importance of early detection and treatment.
In conclusion, the North America meningococcal meningitis treatment market is driven by the high incidence of the disease in the region. Thus, North America is expected to possess 47% market share for meningococcal meningitis treatment market in 2023.
Development of new antibiotics propelling growth of Meningococcal Meningitis Treatment Market
The high incidence of the disease in certain regions of the continent, such as the meningitis belt in sub-Saharan Africa, is creating a growing demand for treatment options. The availability of vaccines is contributing to the growth of the market. The WHO recommends vaccination for individuals living in countries with a high incidence of the disease and for those traveling to regions where the disease is more common. Routine vaccination for adolescents is also recommended in many countries.
Advances in treatment options and technologies are also driving the growth of the market in Europe. The development of new antibiotics, as well as the use of advanced diagnostic and monitoring tools, is helping to improve outcomes for individuals with meningococcal meningitis.
Government initiatives and healthcare policies aimed at reducing the burden of meningococcal meningitis are also contributing to the growth of the market. For example, in some countries, routine vaccination against meningococcal meningitis is now a part of the national immunization program. Thus, Europe is expected to possess 42% market share for meningococcal meningitis treatment market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Early treatment with antibiotics reducing complications for Meningococcal Meningitis
Antibiotic therapy is considered the best treatment for meningococcal meningitis because it is effective in killing the bacteria that cause the infection. Meningococcal meningitis is caused by the Neisseria meningitidis bacteria, which can rapidly spread through the bloodstream and infect the lining of the brain and spinal cord. Antibiotics work by targeting the bacteria and destroying it, thereby preventing the bacteria from multiplying and causing further damage.
Prompt administration of antibiotics is crucial for successful treatment of meningococcal meningitis because the disease can progress rapidly and cause severe complications, such as brain damage, hearing loss, and even death. Early treatment with antibiotics can significantly reduce the risk of complications and improve the chances of a full recovery. The most commonly used antibiotics for the treatment of meningococcal meningitis are penicillin, ampicillin, ceftriaxone, and cefotaxime. Thus, antibiotic therapy is expected to possess 45% market share for meningococcal meningitis treatment market in 2023.
Key players in the Meningococcal Meningitis treatment market are Biomed Pvt. Ltd, Novartis, Nuron Biotech, Pfizer, Baxter, Merck & Co., Sanofi, GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., Athlone Laboratories and Wockhardt Ltd.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 178.78 Million |
| Market Value in 2033 | US$ 283 Million |
| Growth Rate | CAGR of 4.7% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The net worth of the market is expected to be US$ 283 million by 2033.
The market is calculated to expand at a CAGR of 4.7% through 2033.
The market expanded at a CAGR of 3.1% from 2018 to 2022.
The market is being shaped by the availability of treatments and surging investment in research and development.
Antibiotic therapy enjoys immense popularity.
1. Executive Summary | Meningococcal Meningitis Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Causative Micro-organism 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Causative Micro-organism, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Causative Micro-organism, 2023 to 2033 5.3.1. Bacterial 5.3.2. Viral 5.3.3. Fungal 5.4. Y-o-Y Growth Trend Analysis By Causative Micro-organism, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Causative Micro-organism, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033 6.3.1. Antibiotic Therapy 6.3.1.1. Penicillin 6.3.1.2. Ampicillin 6.3.1.3. Chloramphenicol 6.3.1.4. Ceftriaxone 6.3.2. Adjunctive Therapy 6.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration , 2023 to 2033 7.3.1. Injectable 7.3.2. Oral 7.4. Y-o-Y Growth Trend Analysis By Route of Administration , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Route of Administration , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Vaccine Type 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By Vaccine Type, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Vaccine Type, 2023 to 2033 8.3.1. Meningococcal Conjugate Vaccine 8.3.2. Meningococcal Polysaccharide Vaccine 8.3.3. Combination Vaccine 8.4. Y-o-Y Growth Trend Analysis By Vaccine Type, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By Vaccine Type, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution channel 9.1. Introduction / Key Findings 9.2. Historical Market Size Value (US$ Million) Analysis By Distribution channel, 2018 to 2022 9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution channel, 2023 to 2033 9.3.1. Hospital Pharmacy 9.3.2. Retail Pharmacy 9.3.3. Online Pharmacy 9.4. Y-o-Y Growth Trend Analysis By Distribution channel, 2018 to 2022 9.5. Absolute $ Opportunity Analysis By Distribution channel, 2023 to 2033 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 10.1. Introduction 10.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 10.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 10.3.1. North America 10.3.2. Latin America 10.3.3. Europe 10.3.4. South Asia 10.3.5. East Asia 10.3.6. Oceania 10.3.7. MEA 10.4. Market Attractiveness Analysis By Region 11. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. USA 11.2.1.2. Canada 11.2.2. By Causative Micro-organism 11.2.3. By Treatment Type 11.2.4. By Route of Administration 11.2.5. By Vaccine Type 11.2.6. By Distribution channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Causative Micro-organism 11.3.3. By Treatment Type 11.3.4. By Route of Administration 11.3.5. By Vaccine Type 11.3.6. By Distribution channel 11.4. Key Takeaways 12. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Brazil 12.2.1.2. Mexico 12.2.1.3. Rest of Latin America 12.2.2. By Causative Micro-organism 12.2.3. By Treatment Type 12.2.4. By Route of Administration 12.2.5. By Vaccine Type 12.2.6. By Distribution channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Causative Micro-organism 12.3.3. By Treatment Type 12.3.4. By Route of Administration 12.3.5. By Vaccine Type 12.3.6. By Distribution channel 12.4. Key Takeaways 13. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Germany 13.2.1.2. United kingdom 13.2.1.3. France 13.2.1.4. Spain 13.2.1.5. Italy 13.2.1.6. Rest of Europe 13.2.2. By Causative Micro-organism 13.2.3. By Treatment Type 13.2.4. By Route of Administration 13.2.5. By Vaccine Type 13.2.6. By Distribution channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Causative Micro-organism 13.3.3. By Treatment Type 13.3.4. By Route of Administration 13.3.5. By Vaccine Type 13.3.6. By Distribution channel 13.4. Key Takeaways 14. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. India 14.2.1.2. Malaysia 14.2.1.3. Singapore 14.2.1.4. Thailand 14.2.1.5. Rest of South Asia 14.2.2. By Causative Micro-organism 14.2.3. By Treatment Type 14.2.4. By Route of Administration 14.2.5. By Vaccine Type 14.2.6. By Distribution channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Causative Micro-organism 14.3.3. By Treatment Type 14.3.4. By Route of Administration 14.3.5. By Vaccine Type 14.3.6. By Distribution channel 14.4. Key Takeaways 15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. China 15.2.1.2. Japan 15.2.1.3. South Korea 15.2.2. By Causative Micro-organism 15.2.3. By Treatment Type 15.2.4. By Route of Administration 15.2.5. By Vaccine Type 15.2.6. By Distribution channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Causative Micro-organism 15.3.3. By Treatment Type 15.3.4. By Route of Administration 15.3.5. By Vaccine Type 15.3.6. By Distribution channel 15.4. Key Takeaways 16. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. Australia 16.2.1.2. New Zealand 16.2.2. By Causative Micro-organism 16.2.3. By Treatment Type 16.2.4. By Route of Administration 16.2.5. By Vaccine Type 16.2.6. By Distribution channel 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Causative Micro-organism 16.3.3. By Treatment Type 16.3.4. By Route of Administration 16.3.5. By Vaccine Type 16.3.6. By Distribution channel 16.4. Key Takeaways 17. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 17.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 17.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 17.2.1. By Country 17.2.1.1. GCC Countries 17.2.1.2. South Africa 17.2.1.3. Israel 17.2.1.4. Rest of MEA 17.2.2. By Causative Micro-organism 17.2.3. By Treatment Type 17.2.4. By Route of Administration 17.2.5. By Vaccine Type 17.2.6. By Distribution channel 17.3. Market Attractiveness Analysis 17.3.1. By Country 17.3.2. By Causative Micro-organism 17.3.3. By Treatment Type 17.3.4. By Route of Administration 17.3.5. By Vaccine Type 17.3.6. By Distribution channel 17.4. Key Takeaways 18. Key Countries Market Analysis 18.1. USA 18.1.1. Pricing Analysis 18.1.2. Market Share Analysis, 2022 18.1.2.1. By Causative Micro-organism 18.1.2.2. By Treatment Type 18.1.2.3. By Route of Administration 18.1.2.4. By Vaccine Type 18.1.2.5. By Distribution channel 18.2. Canada 18.2.1. Pricing Analysis 18.2.2. Market Share Analysis, 2022 18.2.2.1. By Causative Micro-organism 18.2.2.2. By Treatment Type 18.2.2.3. By Route of Administration 18.2.2.4. By Vaccine Type 18.2.2.5. By Distribution channel 18.3. Brazil 18.3.1. Pricing Analysis 18.3.2. Market Share Analysis, 2022 18.3.2.1. By Causative Micro-organism 18.3.2.2. By Treatment Type 18.3.2.3. By Route of Administration 18.3.2.4. By Vaccine Type 18.3.2.5. By Distribution channel 18.4. Mexico 18.4.1. Pricing Analysis 18.4.2. Market Share Analysis, 2022 18.4.2.1. By Causative Micro-organism 18.4.2.2. By Treatment Type 18.4.2.3. By Route of Administration 18.4.2.4. By Vaccine Type 18.4.2.5. By Distribution channel 18.5. Germany 18.5.1. Pricing Analysis 18.5.2. Market Share Analysis, 2022 18.5.2.1. By Causative Micro-organism 18.5.2.2. By Treatment Type 18.5.2.3. By Route of Administration 18.5.2.4. By Vaccine Type 18.5.2.5. By Distribution channel 18.6. United kingdom 18.6.1. Pricing Analysis 18.6.2. Market Share Analysis, 2022 18.6.2.1. By Causative Micro-organism 18.6.2.2. By Treatment Type 18.6.2.3. By Route of Administration 18.6.2.4. By Vaccine Type 18.6.2.5. By Distribution channel 18.7. France 18.7.1. Pricing Analysis 18.7.2. Market Share Analysis, 2022 18.7.2.1. By Causative Micro-organism 18.7.2.2. By Treatment Type 18.7.2.3. By Route of Administration 18.7.2.4. By Vaccine Type 18.7.2.5. By Distribution channel 18.8. Spain 18.8.1. Pricing Analysis 18.8.2. Market Share Analysis, 2022 18.8.2.1. By Causative Micro-organism 18.8.2.2. By Treatment Type 18.8.2.3. By Route of Administration 18.8.2.4. By Vaccine Type 18.8.2.5. By Distribution channel 18.9. Italy 18.9.1. Pricing Analysis 18.9.2. Market Share Analysis, 2022 18.9.2.1. By Causative Micro-organism 18.9.2.2. By Treatment Type 18.9.2.3. By Route of Administration 18.9.2.4. By Vaccine Type 18.9.2.5. By Distribution channel 18.10. India 18.10.1. Pricing Analysis 18.10.2. Market Share Analysis, 2022 18.10.2.1. By Causative Micro-organism 18.10.2.2. By Treatment Type 18.10.2.3. By Route of Administration 18.10.2.4. By Vaccine Type 18.10.2.5. By Distribution channel 18.11. Malaysia 18.11.1. Pricing Analysis 18.11.2. Market Share Analysis, 2022 18.11.2.1. By Causative Micro-organism 18.11.2.2. By Treatment Type 18.11.2.3. By Route of Administration 18.11.2.4. By Vaccine Type 18.11.2.5. By Distribution channel 18.12. Singapore 18.12.1. Pricing Analysis 18.12.2. Market Share Analysis, 2022 18.12.2.1. By Causative Micro-organism 18.12.2.2. By Treatment Type 18.12.2.3. By Route of Administration 18.12.2.4. By Vaccine Type 18.12.2.5. By Distribution channel 18.13. Thailand 18.13.1. Pricing Analysis 18.13.2. Market Share Analysis, 2022 18.13.2.1. By Causative Micro-organism 18.13.2.2. By Treatment Type 18.13.2.3. By Route of Administration 18.13.2.4. By Vaccine Type 18.13.2.5. By Distribution channel 18.14. China 18.14.1. Pricing Analysis 18.14.2. Market Share Analysis, 2022 18.14.2.1. By Causative Micro-organism 18.14.2.2. By Treatment Type 18.14.2.3. By Route of Administration 18.14.2.4. By Vaccine Type 18.14.2.5. By Distribution channel 18.15. Japan 18.15.1. Pricing Analysis 18.15.2. Market Share Analysis, 2022 18.15.2.1. By Causative Micro-organism 18.15.2.2. By Treatment Type 18.15.2.3. By Route of Administration 18.15.2.4. By Vaccine Type 18.15.2.5. By Distribution channel 18.16. South Korea 18.16.1. Pricing Analysis 18.16.2. Market Share Analysis, 2022 18.16.2.1. By Causative Micro-organism 18.16.2.2. By Treatment Type 18.16.2.3. By Route of Administration 18.16.2.4. By Vaccine Type 18.16.2.5. By Distribution channel 18.17. Australia 18.17.1. Pricing Analysis 18.17.2. Market Share Analysis, 2022 18.17.2.1. By Causative Micro-organism 18.17.2.2. By Treatment Type 18.17.2.3. By Route of Administration 18.17.2.4. By Vaccine Type 18.17.2.5. By Distribution channel 18.18. New Zealand 18.18.1. Pricing Analysis 18.18.2. Market Share Analysis, 2022 18.18.2.1. By Causative Micro-organism 18.18.2.2. By Treatment Type 18.18.2.3. By Route of Administration 18.18.2.4. By Vaccine Type 18.18.2.5. By Distribution channel 18.19. GCC Countries 18.19.1. Pricing Analysis 18.19.2. Market Share Analysis, 2022 18.19.2.1. By Causative Micro-organism 18.19.2.2. By Treatment Type 18.19.2.3. By Route of Administration 18.19.2.4. By Vaccine Type 18.19.2.5. By Distribution channel 18.20. South Africa 18.20.1. Pricing Analysis 18.20.2. Market Share Analysis, 2022 18.20.2.1. By Causative Micro-organism 18.20.2.2. By Treatment Type 18.20.2.3. By Route of Administration 18.20.2.4. By Vaccine Type 18.20.2.5. By Distribution channel 18.21. Israel 18.21.1. Pricing Analysis 18.21.2. Market Share Analysis, 2022 18.21.2.1. By Causative Micro-organism 18.21.2.2. By Treatment Type 18.21.2.3. By Route of Administration 18.21.2.4. By Vaccine Type 18.21.2.5. By Distribution channel 19. Market Structure Analysis 19.1. Competition Dashboard 19.2. Competition Benchmarking 19.3. Market Share Analysis of Top Players 19.3.1. By Regional 19.3.2. By Causative Micro-organism 19.3.3. By Treatment Type 19.3.4. By Route of Administration 19.3.5. By Vaccine Type 19.3.6. By Distribution channel 20. Competition Analysis 20.1. Competition Deep Dive 20.1.1. Biomed Pvt. Ltd 20.1.1.1. Overview 20.1.1.2. Product Portfolio 20.1.1.3. Profitability by Market Segments 20.1.1.4. Sales Footprint 20.1.1.5. Strategy Overview 20.1.1.5.1. Marketing Strategy 20.1.2. Novartis 20.1.2.1. Overview 20.1.2.2. Product Portfolio 20.1.2.3. Profitability by Market Segments 20.1.2.4. Sales Footprint 20.1.2.5. Strategy Overview 20.1.2.5.1. Marketing Strategy 20.1.3. Nuron Biotech 20.1.3.1. Overview 20.1.3.2. Product Portfolio 20.1.3.3. Profitability by Market Segments 20.1.3.4. Sales Footprint 20.1.3.5. Strategy Overview 20.1.3.5.1. Marketing Strategy 20.1.4. Pfizer 20.1.4.1. Overview 20.1.4.2. Product Portfolio 20.1.4.3. Profitability by Market Segments 20.1.4.4. Sales Footprint 20.1.4.5. Strategy Overview 20.1.4.5.1. Marketing Strategy 20.1.5. Baxter 20.1.5.1. Overview 20.1.5.2. Product Portfolio 20.1.5.3. Profitability by Market Segments 20.1.5.4. Sales Footprint 20.1.5.5. Strategy Overview 20.1.5.5.1. Marketing Strategy 20.1.6. Merck & Co. 20.1.6.1. Overview 20.1.6.2. Product Portfolio 20.1.6.3. Profitability by Market Segments 20.1.6.4. Sales Footprint 20.1.6.5. Strategy Overview 20.1.6.5.1. Marketing Strategy 20.1.7. Sanofi 20.1.7.1. Overview 20.1.7.2. Product Portfolio 20.1.7.3. Profitability by Market Segments 20.1.7.4. Sales Footprint 20.1.7.5. Strategy Overview 20.1.7.5.1. Marketing Strategy 20.1.8. GlaxoSmithKline Plc. 20.1.8.1. Overview 20.1.8.2. Product Portfolio 20.1.8.3. Profitability by Market Segments 20.1.8.4. Sales Footprint 20.1.8.5. Strategy Overview 20.1.8.5.1. Marketing Strategy 20.1.9. F. Hoffmann-La Roche Ltd. 20.1.9.1. Overview 20.1.9.2. Product Portfolio 20.1.9.3. Profitability by Market Segments 20.1.9.4. Sales Footprint 20.1.9.5. Strategy Overview 20.1.9.5.1. Marketing Strategy 20.1.10. Athlone Laboratories 20.1.10.1. Overview 20.1.10.2. Product Portfolio 20.1.10.3. Profitability by Market Segments 20.1.10.4. Sales Footprint 20.1.10.5. Strategy Overview 20.1.10.5.1. Marketing Strategy 20.1.11. Wockhardt Ltd. 20.1.11.1. Overview 20.1.11.2. Product Portfolio 20.1.11.3. Profitability by Market Segments 20.1.11.4. Sales Footprint 20.1.11.5. Strategy Overview 20.1.11.5.1. Marketing Strategy 21. Assumptions & Acronyms Used 22. Research Methodology
Industrial Automation
January 2022
REP-GB--86
March 2024
235 pages
Explore Healthcare Insights
View Reports
Meningococcal Meningitis Treatment Market
